Major Depressive Disorder Steroid Treatment Gets FDA Fast Track Designation
Major depressive disorder could find a potential new treatment in SAGE-217, which received FDA fast track designation.
Major depressive disorder could find a potential new treatment in SAGE-217, which received FDA fast track designation.
Patients with major depressive disorder are involved in a trial to determine the efficacy of d-Methadone.